Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
Standard BioTools (NASDAQ: LAB) announced it will publish third quarter 2025 financial results on Tuesday, November 4, 2025.
The company said the results will be released after U.S. market close.
Standard BioTools (NASDAQ: LAB) ha annunciato che pubblicherà i risultati finanziari del terzo trimestre 2025 martedì 4 novembre 2025.
L'azienda ha dichiarato che i risultati saranno pubblicati dopo la chiusura del mercato statunitense.
Standard BioTools (NASDAQL: LAB) anunció que publicará los resultados financieros del tercer trimestre de 2025 el martes 4 de noviembre de 2025.
La compañía dijo que los resultados se divulgarán después del cierre del mercado estadounidense.
Standard BioTools (NASDAQ: LAB)는 2025년 3분기 재무 결과를 2025년 11월 4일 화요일에 발표할 예정이라고 밝혔다.
회사는 결과가 미국 시장 마감 후에 공개될 것이라고 말했다.
Standard BioTools (NASDAQ : LAB) a annoncé qu'il publiera les résultats financiers du troisième trimestre 2025 le mardi 4 novembre 2025.
La société a déclaré que les résultats seront publiés après la clôture du marché américain.
Standard BioTools (NASDAQ: LAB) gab bekannt, dass es die Finanzergebnisse für das dritte Quartal 2025 am Dienstag, den 4. November 2025 veröffentlichen wird.
Das Unternehmen sagte, die Ergebnisse würden nach Börsenschluss in den USA veröffentlicht.
Standard BioTools (NASDAQ: LAB) أعلنت أنها ستنشر نتائج الأعمال للربع الثالث 2025 في الثلاثاء 4 نوفمبر 2025.
وقالت الشركة إن النتائج ستُصدر بعد إغلاق السوق الأميركي.
Standard BioTools (NASDAQ: LAB) 宣布将于 2025 年第三季度财报 于 2025 年 11 月 4 日，星期二 公布。
公司表示，结果将 在美国市场收盘后发布。
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2025 Standard BioTools Inc. All rights reserved.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Investor Contact:
ir@standardbio.com
FAQ
When will Standard BioTools (LAB) release third quarter 2025 results?
Will Standard BioTools (LAB) report Q3 2025 results during or after market hours?
What date should investors mark for Standard BioTools (LAB) Q3 2025 earnings?
Is the Standard BioTools (LAB) Q3 2025 release scheduled for a weekday or weekend?
Does the announcement state the exact time for Standard BioTools (LAB) Q3 2025 results?
What should shareholders expect on November 4, 2025 regarding Standard BioTools (LAB)?
